JNJ

NEW YORK STOCK EXCHANGE, INC. · Pharmaceuticals

Johnson & Johnson

Q: Is JNJ stock a good investment?

Johnson & Johnson offers defensive stability through diversified healthcare operations and a history of consistent dividend growth. The stock trades at a reasonable P/E with solid free cash flow generation. Risks include patent expirations on major drugs like Stelara and Remicade, litigation liabilities (talc, opioids), and pricing pressure from government healthcare reforms. Medical device sales can slow during elective surgery declines, impacting MedTech revenue growth.

Q: Who are Johnson & Johnson's main competitors?

Johnson & Johnson competes with Pfizer and Merck in pharmaceuticals, Medtronic and Abbott Laboratories in medical devices, Stryker in orthopedics and surgical equipment, and AbbVie in immunology. The competitive landscape varies by segment, with pharmaceutical competition driven by drug efficacy and device competition based on innovation and hospital relationships.

Q: Does Johnson & Johnson pay dividends?

Johnson & Johnson has increased its dividend for over 60 consecutive years, earning it Dividend King status—one of the longest dividend growth streaks in the market. The company maintains a sustainable payout ratio and prioritizes annual dividend increases as a core shareholder return strategy. JNJ's combination of yield and growth appeals to investors seeking reliable income with inflation protection.

Q: How much does JNJ stock cost right now?

JNJ last closed at $231.29, up 1.27% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $149.04 and a high of $251.71. The current price represents 80% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

Q: What is the analyst consensus for JNJ?

Among 31 analysts covering JNJ, the consensus rating is Buy — 21 rate it a buy, 10 hold, and 0 sell. The average price target sits at $299.55, implying 30% upside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Q: Does Johnson & Johnson make money?

Johnson & Johnson generated $93.33B in revenue during fiscal year 2026, with $26.56B reaching the bottom line as net income. The net profit margin of 28.5% is strong by most industry standards.

Q: Is JNJ stock expensive based on earnings?

JNJ trades at a P/E ratio of 26.13 on trailing earnings of $8.65 per share. That's roughly in line with the broader market average of ~20-25x. Comparing this multiple against Pharmaceuticals sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

S&P 500 Dow Jones Mega-Cap Stocks Blue Chip Stocks Pharmaceutical Stocks Healthcare Stocks Best Dividend Stocks

$231.29

+2.90 (+1.27%)

As of Jun 22, 9:30 PM ET ·

Day Range $227.50 — $231.45

52W Range $149.04 — $251.71

Performance

1D —

1W —

1M —

3M —

6M +11.40%

1Y +52.85%

YTD +11.55%

Open$228.95

Previous Close$228.39

Day High$231.45

Day Low$227.50

52W High$251.71

52W Low$149.04

Volume—

Avg Volume8.91M

Market Cap549.78B

P/E Ratio26.13

EPS$8.65

SectorPharmaceuticals

Technical Indicators

Full analysis →

SMA 50 $219.25 Above

SMA 200 $185.17 Above

RSI (14) 88.6 Overbought

Trend Golden Cross Bullish

Analyst Ratings

Buy

31 analysts

21 Buy 10 Hold 0 Sell

Price Target +29.5% upside

Current
$231.29

Target
$299.55

$223.02 $299.55 avg $400.15

Key Financials

	FY 2026	FY 2025	FY 2024
Revenue	93.33B	88.38B	81.19B
Net Income	26.56B	22.64B	16.19B
Profit Margin	28.5%	27.0%	19.9%
EBITDA	39.72B	35.73B	32.24B
Free Cash Flow	—	—	20.95B
Rev Growth	+5.6%	+5.6%	+12.0%
Debt/Equity	0.59	0.59	0.42

Dividend

Dividend Yield2.35%

Annual Dividend$5.14

Payout Ratio46.2%

Frequencyquarterly

Ex-DividendFeb 20, 2026

Pay DateMar 8, 2026

Recent Insider Activity

All Insiders →

Date	Insider	Type	Shares	Price	Value
Jun 12	Wengel Kathryn E	Exercise	124,288	$115.67	$14.38M
Jun 12	Wengel Kathryn E	Sale	114,288	$241.15	$27.56M
Jun 12	Wengel Kathryn E	Exercise	32,965	$0.00	—
May 4	REED JOHN C	Exercise	35,913	$0.00	—
May 4	REED JOHN C	Exercise	0	$0.00	—

About Johnson & Johnson

Johnson & Johnson, based in New Brunswick, New Jersey, is a diversified healthcare company operating in pharmaceuticals, consumer health products, and medical devices. The company develops and manufactures medications for various therapeutic areas including cardiovascular, immunology, and oncology. Johnson & Johnson is one of the world's largest healthcare companies with leading positions in prescription pharmaceuticals and consumer wellness. The company operates across multiple healthcare segments serving patients and consumers globally.

Pharmaceuticals Peers

Symbol	Name	Price	Change	P/E	Mkt Cap
LLY	Eli Lilly and Co.	$1,102.08	+0.32%	40.9	1.03T
MRK	Merck & Co. Inc.	$115.48	+1.41%	31.5	281.24B
PFE	Pfizer Inc.	$25.08	-0.52%	19.2	143.68B
BMY	Bristol-Myers Squibb Co	$54.70	+1.30%	18.5	110.27B
ZTS	Zoetis Inc	$75.89	-3.58%	12.5	33.00B
RPRX	Royalty Pharma Plc- Cl A	$53.57	+1.15%	36.9	30.50B

JNJ Frequently Asked Questions

What does Johnson & Johnson do?

Johnson & Johnson operates two primary segments following its 2023 consumer health spinoff: Innovative Medicine (prescription pharmaceuticals in oncology, immunology, and cardiovascular) and MedTech (surgical equipment, orthopedics, vision care). Revenue comes from patented drugs and medical devices sold to hospitals, clinics, and patients globally. The pharmaceutical division drives growth through high-margin specialty drugs, while MedTech provides stable cash flow from recurring device sales and consumables used in surgical procedures.

Is JNJ stock a good investment?

Johnson & Johnson offers defensive stability through diversified healthcare operations and a history of consistent dividend growth. The stock trades at a reasonable P/E with solid free cash flow generation. Risks include patent expirations on major drugs like Stelara and Remicade, litigation liabilities (talc, opioids), and pricing pressure from government healthcare reforms. Medical device sales can slow during elective surgery declines, impacting MedTech revenue growth.

Who are Johnson & Johnson's main competitors?

Johnson & Johnson competes with Pfizer and Merck in pharmaceuticals, Medtronic and Abbott Laboratories in medical devices, Stryker in orthopedics and surgical equipment, and AbbVie in immunology. The competitive landscape varies by segment, with pharmaceutical competition driven by drug efficacy and device competition based on innovation and hospital relationships.

Does Johnson & Johnson pay dividends?

Johnson & Johnson has increased its dividend for over 60 consecutive years, earning it Dividend King status—one of the longest dividend growth streaks in the market. The company maintains a sustainable payout ratio and prioritizes annual dividend increases as a core shareholder return strategy. JNJ's combination of yield and growth appeals to investors seeking reliable income with inflation protection.

How much does JNJ stock cost right now?

JNJ last closed at $231.29, up 1.27% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $149.04 and a high of $251.71. The current price represents 80% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

What is the analyst consensus for JNJ?

Among 31 analysts covering JNJ, the consensus rating is Buy — 21 rate it a buy, 10 hold, and 0 sell. The average price target sits at $299.55, implying 30% upside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Does Johnson & Johnson make money?

Johnson & Johnson generated $93.33B in revenue during fiscal year 2026, with $26.56B reaching the bottom line as net income. The net profit margin of 28.5% is strong by most industry standards.

Is JNJ stock expensive based on earnings?

JNJ trades at a P/E ratio of 26.13 on trailing earnings of $8.65 per share. That's roughly in line with the broader market average of ~20-25x. Comparing this multiple against Pharmaceuticals sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

Is JNJ stock going up or down?

Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: +11.40% (6M), +52.85% (1Y), +11.55% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether JNJ is outperforming or lagging the broader market.